Search

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Ophthalmology in ancient india, Sushruta’s time and the modern era

While reading an article related to the history of Indian ophthalmology, I came across this description of a surgical procedure: “The doctor warmed the patient’s eye with the breath of his mouth. He rubbed the closed eye of the patient...

Clinical and management strategies in glaucoma practice: perspectives from international glaucoma specialists

Management options and outcomes in glaucoma practice were reviewed at the 7th Moorfields International Glaucoma Symposium, held in London on 24 January 2015. This article summarises perspectives from international glaucoma specialists on debated issues in topical therapy, glaucoma surgery, diagnostic...

The past and the future for paediatric ophthalmology

The past 25 years have seen remarkable advances in clinical eye care for children in the UK. This has led to both improved outcomes and better patient and family experiences. There have been substantial changes to patient pathways, major advances...

What’s next in retinal imaging? Faster, deeper and full-on

Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Part 1: The Arclight Project – Frugal tech for sight

Click here for Part 2 on this topic, and here for Part 3 The Arclight Project is a mix of frugal design, manufacturing, distribution, teaching, research, and advocacy, all wrapped up in a social enterprise based at the University of...

See sweet to C-suite: Imran Rahman

See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...

Danger Zone: Miles Hilton-Barber

“Life is either a daring adventure, or nothing at all” – Helen Keller, deafblind American author, activist, and disability rights advocate I have always had a thirst for adventure, even if it has been predominantly from the comfort of my...

The founder of modern ophthalmology: Sir William Stewart Duke-Elder

A recent article in Eye News by Blaikie & King highlighted the extraordinary contribution made to the profession of ophthalmology by Sir William Stewart Duke-Elder. The author felt it appropriate to take a further in-depth look at the remarkable career...

Progress in retinal disease management: Highlights of the Retina Day, RCOphth 2025 Annual Congress

The Retina Day meeting at the Royal College of Ophthalmologists (RCOphth) 2025 Annual Congress in Liverpool was held on 22 May 2025. This report highlights 10 selected topics of interest to subspecialists and general ophthalmologists. Decarbonising anti-VEGF clinics (or making...